Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.Even very well-run companies will eventually fall upon hard times. That's the backstory you need to keep in mind when you examine Bristol Myers Squibb (BMY +2.99%) and Pfizer (PFE +0.29%). Here's why contrarians and turnaround lovers will likely find Pfizer the better turnaround play. Comparisons are importantBenjamin Graham is often considered the father of fundamental ...